REGN
NASDAQ · Biotechnology
Regeneron Pharmaceuticals
$623.43
+5.40 (+0.87%)
REGN News16 articles
AbbVie to Buy Apogee in $10.9B Deal to Boost Immunology Pipeline
AbbVie acquires Apogee Therapeutics for $10.9 billion, paying a 49.49% premium for experimental eczema drug zumilokibart, as it seeks to bolster its immunology franchise.
AbbVie Nears $10.9B Apogee Takeover, Healthcare Stocks in Focus
AbbVie is reportedly close to acquiring Apogee Therapeutics for $10.9 billion in cash, offering a roughly 60% premium. A deal could be announced Monday, putting healthcare stocks in the spotlight.
Outlook Therapeutics Surges on FDA Review of Wet AMD Treatment
Outlook Therapeutics shares jumped 30% after the FDA accepted its resubmitted BLA for ONS-5010/LYTENAVA, setting a PDUFA target date of July 29, 2026.
Parabilis Medicines Rockets 58% in Nasdaq Debut After Record $670M IPO
Parabilis Medicines (PBLS) closed at $31.60 on its first trading day, a 58% jump from the $20 IPO price, after raising $670 million.
Wall Street Rally Falters as Oil and Yields Weigh on Tech
U.S. stocks were mixed Monday as rising oil and Treasury yields pressured tech. The Nasdaq slid 0.5%, while energy stocks gained. Dominion Energy jumped 9.4% on merger news.
Regeneron Plunges 10% on Melanoma Drug Trial Failure
Regeneron Pharmaceuticals shares dropped 9.8% Monday after its late-stage melanoma drug trial with fianlimab failed to meet its primary endpoint, missing statistical significance versus Merck's Keytruda.
Wall Street Slips as Tech Retreats, Bond Yields Stay Elevated
U.S. stocks declined Monday as technology shares lost momentum ahead of Nvidia's earnings, while rising oil and elevated bond yields kept inflation concerns in focus.
Dow Edges Higher as Treasury Yields Retreat, Bond Warning Persists
The Dow Jones rose 0.22% on Monday as Treasury yields eased, but bond market warnings remain as oil prices stay elevated. Dominion Energy surged on a $66.8 billion NextEra deal.
Dow Inches Higher, Nasdaq Slips as Bond Yield Retreat Fails to Calm Markets
Stocks were mixed Monday as the Dow edged up but the Nasdaq fell, with bond yields pulling back from recent highs. Dominion Energy jumped on a $66.8B acquisition by NextEra, while Regeneron slid on a trial miss.
Regeneron Shares Slide After Melanoma Combo Misses Key Goal
Regeneron shares tumbled 11.8% in premarket trading after its melanoma drug combo missed statistical significance on progression-free survival versus Keytruda.
Bayer's $2.45B Perfuse Buy Aims to Revitalize Eye Drug Pipeline
Bayer acquires Perfuse Therapeutics for up to $2.45 billion to secure Phase II eye drug PER-001, aiming to bolster its ophthalmology unit as Eylea sales slip.
Regeneron Q1 Results Top Estimates, Eylea Challenges Loom
Regeneron reported strong Q1 results with revenue up 19% and earnings above estimates, but Eylea sales declined and an FDA delay on a new syringe manufacturer weighs on shares.
Regeneron Stock Rises on Drug Pricing Deal, Free Gene Therapy Offer
Regeneron shares gained 2.6% Thursday following a drug-pricing pact with the U.S. and a plan to offer its new gene therapy Otarmeni at no cost. Analysts remain optimistic ahead of Q1 results.
Pfizer Shares Dip Amid Market Selloff, Weight-Loss Drug Approved in China
Pfizer shares declined 1.6% on Thursday, caught in a broad market downturn. The company navigates falling COVID product revenue while advancing its pipeline, including a new weight-loss drug approval in China.
Pfizer Shares Dip Amid Vaccine Policy Clarity, Eczema Drug Progress
Pfizer shares declined slightly as regulatory scrutiny of mRNA vaccines eased, offset by positive mid-stage trial results for its experimental eczema drug tilrekimig.
Pfizer's Eczema Candidate Tilrekimig Advances, Eyes Dupixent Rivalry
Pfizer announced its experimental eczema drug tilrekimig achieved its main goal in a mid-stage study, showing significant symptom improvement. The company plans to initiate a pivotal Phase 3 trial later this year.